MARC ayrıntıları
000 -BAŞLIK |
Sabit Uzunluktaki Kontrol Alanı |
05170na a2200697 4500 |
001 - KONTROL NUMARASI |
Control Dosyası |
56069 |
003 - KONTROL NUMARASI KİMLİĞİ |
Kontrol Alanı |
koha_MIRAKIL |
005 - EN SON İŞLEM TARİHİ ve ZAMANI |
Kontrol Alanı |
20221103143646.0 |
008 - SABİT UZUNLUKTAKİ VERİ ÖGELERİ - GENEL BİLGİ |
Sabit Alan |
111030b tu 000 0 |
020 ## - ISBN - ULUSLARARASI STANDART KİTAP NUMARASI |
Isbn |
0896034771 |
040 ## - KATALOGLAMA KAYNAĞI |
Özgün Kataloglama Kurumu |
CY-NiCIU |
Kataloglama Dili |
tur |
Çeviri Kurumu |
CY-NiCIU |
Açıklama Kuralları |
rda |
041 ## - DİL KODU |
Metin ya da ses kaydının dil kodu |
English |
082 ## - DEWEY ONU SINIFLAMA SİSTEMİ |
Sınıflama Numarası |
616.042 |
Cutter numarası |
T44 1998 |
245 ## - ESER ADI BİLDİRİMİ |
Başlık |
Therapeutic applications of ribozymes |
Sorumluluk Bildirimi |
Editor: Kevin J. Scanlon |
260 ## - YAYIN, DAĞITIM, VB. |
Yayın Yeri |
U.S.A. |
Yayınevi |
Humana Press |
Yayın Tarihi |
1998 |
264 1# - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
Place of production, publication, distribution, manufacture |
: |
Name of producer, publisher, distributor, manufacturer |
, |
Date of production, publication, distribution, manufacture, or copyright notice |
. |
300 ## - FİZİKSEL TANIMLAMA |
Sayfa, Cilt vb. |
XIV, 462 p. |
Diğer fiziki detaylar |
tab., ill. |
Boyutları |
23.8 cm. |
336 ## - CONTENT TYPE |
Source |
rdacontent |
Content type term |
text |
Content type code |
txt |
337 ## - MEDIA TYPE |
Source |
rdamedia |
Media type term |
unmediated |
Media type code |
n |
338 ## - CARRIER TYPE |
Source |
rdacarrier |
Carrier type term |
volume |
Carrier type code |
nc |
504 ## - BİBLİYOGRAFİ NOTU |
Bibliyografi Notu |
Includes index. (447-462 p.) |
650 ## - KONU BAŞLIĞI EK GİRİŞ - KONU TERİMİ |
Konusal terim veya coğrafi ad |
Hastalıklar |
650 ## - KONU BAŞLIĞI EK GİRİŞ - KONU TERİMİ |
Konusal terim veya coğrafi ad |
Diseases |
650 ## - KONU BAŞLIĞI EK GİRİŞ - KONU TERİMİ |
Konusal terim veya coğrafi ad |
Catalytic RNA--Therapeutic use |
650 ## - KONU BAŞLIĞI EK GİRİŞ - KONU TERİMİ |
Konusal terim veya coğrafi ad |
Katalitik RNA - Tedavi amaçlı kullanım |
650 ## - KONU BAŞLIĞI EK GİRİŞ - KONU TERİMİ |
Konusal terim veya coğrafi ad |
Catalytic RNA--Laboratory manuals |
650 ## - KONU BAŞLIĞI EK GİRİŞ - KONU TERİMİ |
Konusal terim veya coğrafi ad |
Katalitik RNA - Laboratuvar kılavuzları |
700 ## - EK GİRİŞ - KİŞİ ADI |
Yazar Adı (Kişi adı) |
Editor,: Scanlon,Kevin J. |
İsimle beraber tarih varsa (doğum-ölüm) |
1947- |
942 ## - EK GİRİŞ ÖGELERİ (KOHA) |
Sınıflama Kaynağı |
Dewey Onlu Sınıflama Sistemi |
Materyal Türü |
Books |
505 1# - İÇİNDEKİLER NOTU |
Statement of responsibility |
Philip Hendry. Trevor J. Lockett, and Maxine J. McCall |
Title |
Small Efficient Hammerhead Ribozymes |
505 1# - İÇİNDEKİLER NOTU |
Statement of responsibility |
Arnold Hampel |
Title |
The Hairpin Ribozyme: Discovery and Development for Gene Therapy |
505 1# - İÇİNDEKİLER NOTU |
Statement of responsibility |
N.Kyle Tanner |
Title |
Molecular Manipulations of the Catalytic RNAs From the Human Hepatitis |
505 1# - İÇİNDEKİLER NOTU |
Statement of responsibility |
Lun-Quab Sun, Wayne Gerlach. and Geoff Symonds |
Title |
The Design, Production , and Validation of an Anti-HIV Type 1 Ribozyme |
505 1# - İÇİNDEKİLER NOTU |
Statement of responsibility |
Eric M. Poeschia, Mang Yu, Mark C. Leavitt. and Flossie Wong-Staal/ |
Title |
Methods For Treating HIV by Gene Therapy Using Ribozymes |
505 1# - İÇİNDEKİLER NOTU |
Statement of responsibility |
Jun Ohkawa, Yutaka Takebe, and Kazunari Taira |
Title |
An Expression Vector for Multiple Ribozymes |
505 1# - İÇİNDEKİLER NOTU |
Statement of responsibility |
Gerd Hobom and Annette Menke |
Title |
Viral RNA Targets for Ribozymes : Influenza A virus |
505 1# - İÇİNDEKİLER NOTU |
Statement of responsibility |
Fritz von Welzsacker, Hubert E.Blum, and Jack R. Wands |
Title |
Hammerhead Ribozyme-Mediated Cleavage of Hepatitis B Virus RNA |
505 1# - İÇİNDEKİLER NOTU |
Statement of responsibility |
Glenn H. Cantor |
Title |
Bovine Leukemia Virus Ribozymes |
505 1# - İÇİNDEKİLER NOTU |
Statement of responsibility |
David Y. Bouffard |
Title |
Use of Ribozymes to Specifically Alter the MDR-1 Phenotype |
505 1# - İÇİNDEKİLER NOTU |
Statement of responsibility |
Akira Irie, Jerry Tsai, and Mohammed Kashani -Sabet |
Title |
Adenoviral-Mediated Anti-H-ras Ribozyme for the Treatment of Bladder Cancer |
505 1# - İÇİNDEKİLER NOTU |
Statement of responsibility |
Tsukasa Ohkawa and Mohammed Kashani-Sabet |
Title |
Tissue-Specific Delivery of an Anti-H-ras Ribozyme Against Malignant Melanoma |
505 1# - İÇİNDEKİLER NOTU |
Statement of responsibility |
Hiroshi Kijima, David Y. Bouffard, and Kevin J. Scanlon |
Title |
Ribozymes as a Novel Approach for the Treatment of Human Pancreatic Carcinoma |
505 1# - İÇİNDEKİLER NOTU |
Statement of responsibility |
Alex W. Tong, Yu-An Zhang, John Nemunaitis and Gabriele Mues |
Title |
K-ras Ribozyme for Lung Cancer |
505 1# - İÇİNDEKİLER NOTU |
Statement of responsibility |
Toshiya Suzuki,Lisa D. Curclo, Jerry Tsai, and Mohammed Kashani-Sabet |
Title |
Anti-C-erb-B-2 Ribozyme for Breast Cancer |
505 1# - İÇİNDEKİLER NOTU |
Statement of responsibility |
Gunhild M Maelandsmo, Inge Kjonniksen, Elvind Hovig, Kevin J.Scanlon, and Oystein Fodstad |
Title |
Ribozymes: Applications in Cancer Metastasis Research |
505 1# - İÇİNDEKİLER NOTU |
Statement of responsibility |
Mouldy Sloud |
Title |
Preformed Ribozymes: Strategies for Design and In Vivo Application as Anticytokine Agents |
505 1# - İÇİNDEKİLER NOTU |
Statement of responsibility |
Lance H.Leopold, Scott K. Shore, Ramana M.V. Reddy and E. Premkumar Reddy |
Title |
Folate-Polysine-Mediated Delivery of a Multiunit Anti-BAR/ABL Ribozyme to BCR/ABL-Transformed 32D Cells |
505 1# - İÇİNDEKİLER NOTU |
Statement of responsibility |
Hiromichi Matsushita, Hiroyuki Kobayashi, Masahiro Kizaki, and Yasuo Ikeda |
Title |
Ribozymes Targeted Against AML1/MTG8: Evaluation of Ribozyme Efficiency in a cell-Free System and Transfection with Cationic Lipsome |
505 1# - İÇİNDEKİLER NOTU |
Statement of responsibility |
Frank Czubayka, Anke M.Schulte, and Anton Wellstein |
Title |
Ribozyme Targeting of the Growth Factor Pleiotrophin |
505 1# - İÇİNDEKİLER NOTU |
Statement of responsibility |
Thale C. Javis, Dennis Macejak, and Larry Couture |
Title |
Ribozyme-Mediated Inhibition of Cell Proliferation : A Model for Identifying and Refining a Therapeutic Ribozyme |
505 1# - İÇİNDEKİLER NOTU |
Statement of responsibility |
Mariyn Smedman and Robert B.Denman |
Title |
Inhibition of βAPP Synthesis by Ribozymes and Oligonucleotides in a Coupled Reticulocyte Transcription Transcription Translation System |
505 1# - İÇİNDEKİLER NOTU |
Statement of responsibility |
Joohun Ha |
Title |
Selective Modification of Fatty Acid Synthesis Pathway by Expression of an Acetyl-CoA Carboxylase-Specific Ribozyme Gene |
505 1# - İÇİNDEKİLER NOTU |
Statement of responsibility |
S. Petter Lyngstadaas, Brian S Sproat, Martina Biaschke Janos Ludwig, Thomas Rupp, and Hans P. Prydz |
Title |
In Vivo Knockout of a Tissue-Specific Gene by Synthetic Ribozymes |
505 1# - İÇİNDEKİLER NOTU |
Statement of responsibility |
Shimon Efrat |
Title |
Ribozyme-Mediated Downregulation of Gene Expression in Transgenic Mice |
505 1# - İÇİNDEKİLER NOTU |
Statement of responsibility |
Yan Yuan and Fenyong Liu |
Title |
Targeted Cleavage of RNA Using External Guide Sequences and Eukaryotic RNase P |
505 1# - İÇİNDEKİLER NOTU |
Statement of responsibility |
Yan Yuan |
Title |
Application of In Vitro Selection in Design of External Guide Sequences That Direct Efficient Cleavage of RNA by RNase P |
505 1# - İÇİNDEKİLER NOTU |
Statement of responsibility |
Katalin Kariko and Elliot S. Barnathan |
Title |
A PCR-Based Approach to Hammerhead Ribozyme Synthesis |
505 1# - İÇİNDEKİLER NOTU |
Statement of responsibility |
P. Kamath and E.J.Shillitoe |
Title |
Measurement of Ribozyme Activity Using RNase Protection |
505 0# - İÇİNDEKİLER NOTU |
Miscellaneous information |
447 |
Title |
Index |
505 1# - İÇİNDEKİLER NOTU |
-- |
1 |
505 1# - İÇİNDEKİLER NOTU |
-- |
17 |
505 1# - İÇİNDEKİLER NOTU |
-- |
29 |
505 1# - İÇİNDEKİLER NOTU |
-- |
51 |
505 1# - İÇİNDEKİLER NOTU |
-- |
65 |
505 1# - İÇİNDEKİLER NOTU |
-- |
83 |
505 1# - İÇİNDEKİLER NOTU |
-- |
97 |
505 1# - İÇİNDEKİLER NOTU |
-- |
111 |
505 1# - İÇİNDEKİLER NOTU |
-- |
119 |
505 1# - İÇİNDEKİLER NOTU |
-- |
131 |
505 1# - İÇİNDEKİLER NOTU |
-- |
153 |
505 1# - İÇİNDEKİLER NOTU |
-- |
169 |
505 1# - İÇİNDEKİLER NOTU |
-- |
193 |
505 1# - İÇİNDEKİLER NOTU |
-- |
209 |
505 1# - İÇİNDEKİLER NOTU |
-- |
223 |
505 1# - İÇİNDEKİLER NOTU |
-- |
241 |
505 1# - İÇİNDEKİLER NOTU |
-- |
261 |
505 1# - İÇİNDEKİLER NOTU |
-- |
279 |
505 1# - İÇİNDEKİLER NOTU |
-- |
293 |
505 1# - İÇİNDEKİLER NOTU |
-- |
311 |
505 1# - İÇİNDEKİLER NOTU |
-- |
329 |
505 1# - İÇİNDEKİLER NOTU |
-- |
341 |
505 1# - İÇİNDEKİLER NOTU |
-- |
357 |
505 1# - İÇİNDEKİLER NOTU |
-- |
371 |
505 1# - İÇİNDEKİLER NOTU |
-- |
387 |
505 1# - İÇİNDEKİLER NOTU |
-- |
397 |
505 1# - İÇİNDEKİLER NOTU |
-- |
415 |
505 1# - İÇİNDEKİLER NOTU |
-- |
427 |
505 1# - İÇİNDEKİLER NOTU |
-- |
439 |